Prevalence and severity of liver enzyme alterations in COVID-19 and association with patient-centered outcomes

Belgique Nouvelles Nouvelles

Prevalence and severity of liver enzyme alterations in COVID-19 and association with patient-centered outcomes
Belgique Dernières Nouvelles,Belgique Actualités
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 58 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 71%

Prevalence and severity of liver enzyme alterations in COVID-19 and association with patient-centered outcomes medrxivpreprint georgeinstitute UniofOxford Univ_Lorraine COVID19 coronavirus covid liver enzyme

By Tarun Sai LomteNov 15 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to medRxiv*, researchers examined the prevalence of changes in liver enzymes in coronavirus disease 2019 .

About the study The present study evaluated the prevalence and severity of liver enzyme changes in patients hospitalized with COVID-19 using the ISARIC dataset. All hospitalized patients from January 30, 2021, to September 21, 2021, with suspected/confirmed infection with severe acute respiratory syndrome coronavirus 2 were included in the primary analysis. Patients lacking data on clinical outcomes or liver enzyme tests were excluded.

Related StoriesIn addition, the researchers evaluated the associations between baseline liver enzymes and complications developed in the hospital. Logistic regression was used to determine the relationship between exposure and outcome variables. Sensitivity analysis was performed by including patients with laboratory-confirmed SARS-CoV-2 infection.

Oxygen supplementation was required for 48%, 70.3%, and 75.9% of stage 0, I, and II patients, respectively. Invasive ventilation was required by 9.8% of stage 0 patients, 21.3% of stage I patients, and 27% of stage II patients. The median LoS in the hospital was nine days for stage 0 and II patients and eight days for stage I patients.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

NewsMedical /  🏆 19. in UK

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

How lessons from the HIV epidemic can help combat COVID-19How lessons from the HIV epidemic can help combat COVID-19How lessons from the HIV epidemic can help combat COVID-19 Coronavirus Disease COVID HIV TheLancetHIV UCSF UCBerkeley LSHTM
Lire la suite »

Department for Education shows Lancashire secondary school pupils fell further behind their classmates during CovidDepartment for Education shows Lancashire secondary school pupils fell further behind their classmates during CovidDisadvantaged secondary school pupils in Lancashire fell further behind their classmates during the pandemic, new figures have shown.
Lire la suite »

Lancs firms falsely claimed Covid-19 support loans - and never repaid a pennyLancs firms falsely claimed Covid-19 support loans - and never repaid a pennyTwo firms from Preston and Great Harwood wrongly claimed a combined £97,500
Lire la suite »

Have I dodged Covid and what does it mean?Have I dodged Covid and what does it mean?Why have some people never had Covid and can that lead to better vaccines?
Lire la suite »

New drug shows promise for fighting both COVID-19 and cancerNew drug shows promise for fighting both COVID-19 and cancerWhile vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot get vaccinated or in the event that dangerous new strains of the virus arise that could bypass vaccine protection.
Lire la suite »

Long-term humoral response and its determinants following 2- and 3-dose COVID-19 mRNA vaccinesLong-term humoral response and its determinants following 2- and 3-dose COVID-19 mRNA vaccinesResearchers compared the waning of vaccine-induced immunity from two and three doses of mRNA COVID-19 Pfizer-BioNTech vaccine BNT162b2 by conducting a repeated serological study to assess the prolonged humoral response.
Lire la suite »



Render Time: 2025-04-04 04:32:12